92.20 USD
▼-3.73-3.89%
盘后 112.65 0.00%
2026-09-15
市值
$6.10B
市盈率
—
EPS
-2.02
股息率
—
52 周区间
14.67 – 115.52
成交量
784.62K
Beta
-0.21
目标价
155.00
52W 低 14.6752W 高 115.52
价格走势
公司简介
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an...